Cargando…
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
PURPOSE: Hormone receptor-positive (HR+) tumors have heterogeneous biology and present a challenge for determining optimal treatment. In the Neoadjuvant Breast Registry Symphony Trial (NBRST) patients were classified according to MammaPrint/BluePrint subtyping to provide insight into the response to...
Autores principales: | Whitworth, Pat, Beitsch, Peter, Mislowsky, Angela, Pellicane, James V., Nash, Charles, Murray, Mary, Lee, Laura A., Dul, Carrie L., Rotkis, Michael, Baron, Paul, Stork-Sloots, Lisette, de Snoo, Femke A., Beatty, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306085/ https://www.ncbi.nlm.nih.gov/pubmed/27770345 http://dx.doi.org/10.1245/s10434-016-5600-x |
Ejemplares similares
-
Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
por: Whitworth, Pat, et al.
Publicado: (2014) -
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Baron, Paul, et al.
Publicado: (2015) -
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
por: Whitworth, Pat, et al.
Publicado: (2022) -
Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups
por: Yao, Katharine, et al.
Publicado: (2015) -
High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer
por: Crozier, Jennifer A., et al.
Publicado: (2021)